Zacks Investment Research on MSN
What to expect from Pfizer's non-oncology business in Q4
Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance (1) and reaffirmed its October 29, 2024 full-year 2024 guidance (1). The ...
The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a ...
Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028. Management's attempt to solve the issue has ...
A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback